HOME >> BIOLOGY >> NEWS
Down Syndrome protein reduces tumor growth

Bethesda, MD Scientists have found that overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) blocks the formation of new blood vessels and thus reduces tumor growth. Therapeutics based on this finding may potentially lead to new cancer treatments.

The research appears as the "Paper of the Week" in the November 26 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

Many vascular disorders including atherosclerosis, tumor growth, and inflammation are caused by the activation and dysfunction of the endothelium. This layer of cells lines the inside of blood vessels and regulates many processes including new blood vessel formation, blood vessel diameter, blood clotting, the migration of circulating white blood cells, and the normal release of molecules involved in inflammation

"Because endothelial cells are so active, any perturbation in their function may have undesirable effects," explains Dr. Takashi Minami of the University of Tokyo. "Indeed, endothelial cell dysfunction underlies many disease states in humans, including--but certainly not limited to--stroke, coronary artery disease, cancer and preeclampsia. An important goal in vascular research is to develop new strategies that inhibit endothelial cell dysfunction and abnormal blood vessel formation."

Certain agonists, such as vascular endothelial growth factor and the serine protease thrombin, cause endothelial cells to increase their expression of genes involved in proliferation, inflammation, and thrombosis. Dr. Minami and his colleagues found that these agonists also turn on a gene that produces Down Syndrome Critical Region 1 (DSCR-1), and that DSCR-1 then negatively feeds back on the agonists and shuts off their production. Thus, DSCR-1 acts as a circuit breaker in agonist signaling, and serves in a negative feedback loop to inhibit endothelial cell activation and growth.

More
'"/>

Contact: Nicole Kresge
nkresge@asbmb.org
301-634-7415
American Society for Biochemistry and Molecular Biology
19-Nov-2004


Page: 1 2

Related biology news :

1. Discoverer of Sly Syndrome finds way of delivering medicine to fight rare genetic disorder
2. Researchers discover gene responsible for Restless Legs Syndrome
3. Study uncovers mutation responsible for Noonan Syndrome
4. New findings may lead to treatment for anxiety in Rett Syndrome
5. How Rett Syndrome mutation targets the brain
6. Brain derived neurotrophic factor alleviates disease symptoms in a mouse model of Rett Syndrome
7. Increasing norepinephrine stabilizes breathing patterns in a mouse model of Rett Syndrome
8. Univ. of Chicago scientists find potential cause of breathing problems in Rett Syndrome children
9. New data suggest pramipexole relieves symptoms of Restless Legs Syndrome (RLS) and is well-tolerated
10. Pramipexole delivered sustained efficacy in clinical trial of patients with Restless Legs Syndrome
11. Researchers at Yale identify a genetic link to Tourettes Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Down Syndrome protein reduces tumor growth

(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
(Date:5/26/2015)... May 26, 2015 Tianyin Pharmaceutical Inc. (NYSE ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... the Company,s Annual Meeting of Shareholders for fiscal year ... held at the Company,s office located in ... 9:00 AM (local time in Chengdu, China ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... May 26, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... the study protocol for the company,s Phase IIb trial ... Food and Drug Administration (FDA). The submission was made ... The Phase IIb study of ORMD-0801 for ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Just the ... a long-standing unmet biomedical need does not guarantee immediate ... problem that has seen many prior failures is often ... acceptance and use is an irony that is often ... small, new start-up company, Asymmetrex has found ...
Breaking Biology Technology:TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
Cached News: